A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers
β Scribed by Anneclaire J. De Roos; H. Joachim Deeg; Scott Davis
- Publisher
- Springer Netherlands
- Year
- 2007
- Tongue
- English
- Weight
- 216 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0957-5243
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a firstβline standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH
We studied second primary cancer among 25,947 patients diagnosed with squamous cell carcinoma of the skin (SCC) in Sweden between 1958 and 1992. In total, 5,706 patients developed a second primary cancer at any site, compared with an expected number of 2,651 [standardized incidence ratio (SIR) β«Ψβ¬ 2